Related content

The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions

By Haddad Abdo   Davis Mellar   Lagman Ruth  

Supportive Care in Cancer, Vol. 15, Iss. 3, 2007-03 ,pp. : 251-257

Springer Publishing Company

Access to resources Recommend Favorite

The interactions of lenalidomide with human uptake and efflux transporters and UDP-glucuronosyltransferase 1A1: lack of potential for drug–drug interactions

By Tong Zeen   Yerramilli Usha   Surapaneni Sekhar   Kumar Gondi  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 869-874

Springer Publishing Company

Access to resources Recommend Favorite

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects

By Hamilton Marta   Wolf Julie   Drolet Daniel   Fettner Scott   Rakhit Ashok   Witt Karsten   Lum Bert  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 613-621

Springer Publishing Company

Access to resources Recommend Favorite

Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4

By Zhang Z.-Y.   King B.   Pelletier R.   Wong Y.  

Cancer Chemotherapy and Pharmacology, Vol. 62, Iss. 4, 2008-09 ,pp. : 707-716

Springer Publishing Company

Access to resources Recommend Favorite

Fatal drug-drug interaction of brivudine and capecitabine

By Ratz Bravo Alexandra   Hofer Silvia   Krahenbuhl Stephan   Ludwig Christian  

Acta Oncologica, Vol. 48, Iss. 4, 2009-05 ,pp. : 631-633

Informa Healthcare

Access to resources Recommend Favorite